# A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

> **NCT07233850** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 300 (estimated)

## Conditions studied

- Gastric/Gastroesophageal Junction Adenocarcinoma
- Metastatic Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Oesophageal Cancer

## Interventions

- **DRUG:** SSGJ-706+XELOX
- **DRUG:** SSGJ-706+Bevacizumab+XELOX
- **DRUG:** SSGJ-706+AG
- **DRUG:** SSGJ-706+TP

## Key facts

- **NCT ID:** NCT07233850
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07233850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07233850, "A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07233850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*